Search
 

Ulcerative Colitis Clinical Trials

Browse current & upcoming clinical research / studies on Ulcerative Colitis. There are a total of 263 clinical trials for Ulcerative Colitis in 51 countries with 31 trials currently in the United States. 70 are either active and/or recruiting patients or have not yet been completed. Click the title of each study to get the complete details on eligibility, location & other facts about the study.

Other clinical trials

Definitions
Interventional trials
Determine whether experimental treatments or new ways of using known therapies are safe and effective under controlled environments.
Observational trials
Address health issues in large groups of people or populations in natural settings.
Recruiting
Participants are currently being recruited and enrolled.
Active, not recruiting
Study is ongoing (i.e., patients are being treated or examined), but enrollment has completed.
Not yet recruiting
Participants are not yet being recruited or enrolled.
Enrolling by invitation
Participants are being (or will be) selected from a predetermined population.
Completed
The study has concluded normally; participants are no longer being examined or treated (i.e., last patient's last visit has occurred).
Withdrawn
Study halted prematurely, prior to enrollment of first participant.
Suspended
Recruiting or enrolling participants has halted prematurely but potentially will resume.
Terminated
Recruiting or enrolling participants has halted prematurely and will not resume; participants are no longer being examined or treated.
October 2014 - January 2019
This is a multicenter, Phase III, randomized, double-blind, double-dummy, parall el-group study to evaluate the safety, efficacy, and tolerability of etrolizumab compared with infliximab in treating patients with moderate to severe ulcerativ e colitis (UC) who are naive to tumor necrosis factor (TNF) inhibitors. Patients will be randomized in a 1:1 ratio to receive either etrolizumab (105 mg by subc utaneous injection [SC] every 4 weeks [Q4W]) + placebo (intravenous [IV] infusio n at Weeks 0, 2, and 6, then every 8 weeks) or infliximab (5 mg/kg IV at Weeks 0 , 2, and 6, then every 8 weeks) + placebo (SC Q4W). Time on treatment is 54 week s.
Sponsor: Hoffmann-La Roche
Study type: Interventional
October 2014 - November 2017
This Phase III, double blind, placebo and active comparator controlled, multicen ter study will investigate the efficacy and safety of etrolizumab in induction o f remission in patients with moderately to severely active ulcerative colitis (U C) who are naïve to TNF inhibitors and refractory to or intolerant of prior immu nosuppressant and/or corticosteroid treatment.
Sponsor: Hoffmann-La Roche
Study type: Interventional
September 2014 - April 2026
This two-part, open-label extension (OLE) and safety monitoring (SM) study will examine the efficacy and safety of continued etrolizumab treatment in moderate t o severe ulcerative colitis (UC) patients previously enrolled in etrolizumab Pha se III studies.
Sponsor: Hoffmann-La Roche
Study type: Interventional
September 2014 - September 2017
This Phase III, double blind, placebo and active comparator controlled, multicen ter study will investigate the efficacy and safety of etrolizumab in induction o f remission in patients with moderately to severely active ulcerative colitis (U C) who are naïve to TNF inhibitors and refractory to or intolerant of prior immu nosuppressant and/or corticosteroid treatment.
Sponsor: Hoffmann-La Roche
Study type: Interventional
September 2014 - December 2018
This Phase III, double blind, placebo-controlled, multicenter study will investi gate the efficacy and safety of etrolizumab in maintenance of remission in patie nts with moderately to severely active ulcerative colitis (UC) who are naïve to TNF inhibitors and refractory to or intolerant of prior immunosuppressant and/or corticosteroid treatment.
Sponsor: Hoffmann-La Roche
Study type: Interventional
July 2014 - July 2016
The primary objective of this study is to evaluate the efficacy of golimumab in maintaining a clinical response in participants with moderate-to-severe ulcerative colitis.
Sponsor: Merck Sharp & Dohme Corp.
Study type: Interventional
June 2014 - December 2015
Aim of this study is to determine wether the macromolecular spectral characteristic of ulcerative colitis patients - measured by Physiological Intermolecular Modification Spectroscopy (PIMS) - is a predictive factor for response to Simponi treatment
Sponsor: Kliniken im Naturpark Altmuehltal
Study type: Interventional
June 2014 - January 2016
The aim of this study is to test Eicosapentaenoic free fatty acid's effects on calprotectin levels in IBD patients in clinical remission. During the study fecal calprotectin levels will be measured every 3 months and clinical flares will be registered.
Sponsor: Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi
Study type: Interventional
June 2014 - June 2018
The purpose of the study is to demonstrate the efficacy and safety, and to assess the pharmacokinetics of adalimumab administered subcutaneously (SC) in pediatric subjects with moderate to severe ulcerative colitis (UC).
Sponsor: AbbVie
Study type: Interventional
June 2014 - April 2015
This study is designed to determine whether ulcerative colitis participants prefer delivery of golimumab via a prefilled syringe or the Smartject™ device.
Sponsor: Merck Sharp & Dohme Corp.
Study type: Interventional
Page  
Home  •  Browse by Condition  •  Search Clinical Trials
The information found on this site has been provided by clinicaltrials.gov in accordance with their terms & conditions. Neither we (inclinicaltrials.com), the United States Government, U.S. Department of Health and Human Services, National Institutes of Health, National Library of Medicine, nor any of its agencies, contractors, subcontractors or employees of the United States Government make any warranties, expressed or implied, with respect to data found on this site, and, furthermore, assume no liability, or the results of such use, of any part of the data.